A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease

3期已完成 NCT05931380

适应症	Obesity
分期	3期
申办方	Eli Lilly and Company
状态	已完成
受试者人数	238 人
干预（药物）	Orforglipron
开始日期	2023年7月31日
完成日期	2025年6月19日
结果公布日	2026年7月20日

摘要

The main purpose of this study is to investigate the efficacy and safety of oral orforglipron in participants with obesity disease with obesity-related health problems.

Percent Change From Baseline in Body Weight at Week 72

Baseline, Week 72 · percent change

Placebo QD	-0.63 ± 0.732 percent change
6 mg Orforglipron QD	-5.90 ± 0.866 percent change
12 mg Orforglipron QD	-8.69 ± 1.136 percent change
36 mg Orforglipron QD	-7.93 ± 1.063 percent change

p-value	<.001
LS Mean Difference (Final values)	-5.28 (95% CI -7.52–-3.03)

Percentage of Participants Who Achieved With Greater Than or Equal to (≥) 5% Body Weight Reduction From Baseline

Baseline to Week 72 · Percentage of Participants

Placebo QD	15.00 Percentage of Participants
6 mg Orforglipron QD	45.90 Percentage of Participants
12 mg Orforglipron QD	61.40 Percentage of Participants
36 mg Orforglipron QD	58.33 Percentage of Participants

p-value	<.001
Risk Difference (RD)	30.36 (95% CI 15.09–45.62)

在 BENITIONS 中查看查看 ClinicalTrials.gov 原文

同一适应症的其他试验

Ignite Pilot: Goal Setting in a Digital Weight Loss Intervention — Stanford University
Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects — University of Pennsylvania
Cardiovascular Outcomes in Bariatric Surgery Patients With Type 2 Diabetes — The Cleveland Clinic
Time Restricted Eating for Weight Loss Maintenance — NYU Langone Health
Diabetes Prevention Program Outcomes Study — National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Effect of PDE5 Inhibition on Adipose Metabolism in Humans — Vanderbilt University Medical Center

全部试验

本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。

English 한국어 日本語中文 Русский